These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 31538291)

  • 21. Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome.
    Falzarano C; Lofton T; Osei-Ntansah A; Oliver T; Southward T; Stewart S; Andrisse S
    J Clin Endocrinol Metab; 2022 Jan; 107(1):258-272. PubMed ID: 34491336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
    Kelley CE; Brown AJ; Diehl AM; Setji TL
    World J Gastroenterol; 2014 Oct; 20(39):14172-84. PubMed ID: 25339805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic characteristics of different phenotypes in reproductive-aged women with polycystic ovary syndrome.
    Wen X; Wang L; Bai E
    Front Endocrinol (Lausanne); 2024; 15():1370578. PubMed ID: 39109080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population.
    Salva-Pastor N; López-Sánchez GN; Chávez-Tapia NC; Audifred-Salomón JR; Niebla-Cárdenas D; Topete-Estrada R; Pereznuñez-Zamora H; Vidaltamayo-Ramírez R; Báez-Arellano ME; Uribe M; Nuño-Lámbarri N
    Ann Hepatol; 2020; 19(3):251-257. PubMed ID: 32111488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of socio-demographic and clinical characteristics of PCOS patients attending a tertiary care institute in Colombo.
    Ranathunga I; Athukorala TG; Sumanatilleke MR; Somasundaram NP
    BMC Endocr Disord; 2022 Nov; 22(1):289. PubMed ID: 36411444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease.
    Salva-Pastor N; Chávez-Tapia NC; Uribe M; Nuño-Lámbarri N
    J Steroid Biochem Mol Biol; 2019 Nov; 194():105445. PubMed ID: 31381969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence, etiology and management of non-alcoholic fatty liver disease in patients with polycystic ovary syndrome.
    Makri E; Tziomalos K
    Minerva Endocrinol; 2017 Jun; 42(2):122-131. PubMed ID: 27792214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: associated factors and noninvasive fibrosis staging in a single Brazilian center.
    Taranto DOL; Guimarães TCM; Couto CA; Cândido AL; Azevedo RCS; Mattos FS; Elias MLC; Reis FM; Rocha ALL; Faria LC
    Arch Endocrinol Metab; 2020; 64(3):235-242. PubMed ID: 32555989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome.
    Romanowski MD; Parolin MB; Freitas AC; Piazza MJ; Basso J; Urbanetz AA
    Arq Gastroenterol; 2015; 52(2):117-23. PubMed ID: 26039829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome.
    Wang D; Nan N; Bing H; He B
    Front Endocrinol (Lausanne); 2023; 14():1241734. PubMed ID: 37720537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonalcoholic fatty liver disease in children and adolescents - Relationship with Polycystic Ovary Syndrome.
    Abruzzese GA; Motta AB
    Curr Pharm Des; 2015; 21(35):5144-50. PubMed ID: 26412465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys.
    Ayonrinde OT; Adams LA; Doherty DA; Mori TA; Beilin LJ; Oddy WH; Hickey M; Sloboda DM; Olynyk JK; Hart R
    J Gastroenterol Hepatol; 2016 May; 31(5):980-7. PubMed ID: 26589977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-alcoholic fatty liver disease in polycystic ovarian syndrome in Indian women.
    Siwatch S; Singh V; Dhaliwal LK; Kumari S; Singh K
    J Obstet Gynaecol; 2022 Jul; 42(5):957-961. PubMed ID: 34689689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic steatosis in women with polycystic ovary syndrome.
    Hong X; Guo Z; Yu Q
    BMC Endocr Disord; 2023 Sep; 23(1):207. PubMed ID: 37752440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abdominal Obesity as a Predictive Factor of Nonalcoholic Fatty Liver Disease Assessed by Ultrasonography and Transient Elastography in Polycystic Ovary Syndrome and Healthy Women.
    Tantanavipas S; Vallibhakara O; Sobhonslidsuk A; Phongkitkarun S; Vallibhakara SA; Promson K; Sophonsritsuk A
    Biomed Res Int; 2019; 2019():9047324. PubMed ID: 31467918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance.
    Jones H; Sprung VS; Pugh CJ; Daousi C; Irwin A; Aziz N; Adams VL; Thomas EL; Bell JD; Kemp GJ; Cuthbertson DJ
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3709-16. PubMed ID: 22837189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome - clinical and metabolic aspects and lipoprotein lipase gene polymorphism.
    Bohdanowicz-Pawlak A; Lenarcik-Kabza A; Brona A; Kuliczkowska-Płaksej J; Łaczmański Ł; Zaleska-Dorobisz U; Milewicz A
    Endokrynol Pol; 2014; 65(6):416-21. PubMed ID: 25554608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Interlink Between Metabolic-Associated Fatty Liver Disease and Polycystic Ovary Syndrome.
    Vidal-Cevallos P; Mijangos-Trejo A; Uribe M; Tapia NC
    Endocrinol Metab Clin North Am; 2023 Sep; 52(3):533-545. PubMed ID: 37495343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome.
    Asfari MM; Sarmini MT; Baidoun F; Al-Khadra Y; Ezzaizi Y; Dasarathy S; McCullough A
    BMJ Open Gastroenterol; 2020 Aug; 7(1):. PubMed ID: 32784205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Polycystic ovarian syndrome incidence in young women with non-alcoholic fatty liver disease].
    Ciotta L; Pagano I; Stracquadanio M; Formuso C
    Minerva Ginecol; 2011 Oct; 63(5):429-37. PubMed ID: 21926952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.